

## MANAGEMENT OF A RARE RECURRENCE OF DISTAL TIBIAL GIANT CELL TUMOUR BY SANDWICH TECHNIQUE

Rajesh Kishanrao Ambulgekar<sup>1</sup>, Rohit Thakkar<sup>2</sup>, Rahul Berlia<sup>3</sup>, Pritesh Kothari<sup>4</sup>, Atul Shrivastava<sup>5</sup>, Saurabh Ponde<sup>6</sup>

<sup>1</sup>Professor and HOD, Department of Orthopaedics, Dr. Shankarrao Chavan Government Medical College, Nanded.

<sup>2</sup>Resident, Department of Orthopaedics, Dr. Shankarrao Chavan Government Medical College, Nanded.

<sup>3</sup>Resident, Department of Orthopaedics, Dr. Shankarrao Chavan Government Medical College, Nanded.

<sup>4</sup>Lecturer, Department of Orthopaedics, Dr. Shankarrao Chavan Government Medical College, Nanded.

<sup>5</sup>Lecturer, Department of Orthopaedics, Dr. Shankarrao Chavan Government Medical College, Nanded.

<sup>6</sup>Assistant Professor, Department of Orthopaedics, Dr. Shankarrao Chavan Government Medical College, Nanded.

### ABSTRACT

#### INTRODUCTION

First described by Jaffe et al in 1940, giant cell tumour (GCT) constitutes 20% of all the skeletal neoplasms with a higher rate of recurrence after excision. Most common sites for the involvement are distal femur and proximal tibia followed by the distal end of radius. Ankle and foot involvement is rare <4%. Usually benign, they are locally aggressive and may occasionally undergo malignant transformation. The surgeon needs to strike a balance during treatment between being aggressive in order to reduce the incidence of local recurrence and being conservative in removing the normal bone to attain maximal function.

Current literature suggests that intralesional curettage strikes the best balance between controlling disease and preserving optimum function in the majority of the cases though there may be occasions where the extent of the disease mandates resection to ensure adequate disease clearance.

We report a case of Giant Cell Tumour of distal end of left Tibia in a 32-year-old female patient. Initially the condition was treated by curettage and bone grafting. But, due to recurrence of the condition within 9 months, she was treated with extended curettage using hydrogen peroxide, burr and bone cement as adjuvants and reconstruction using the "SANDWICH" Technique. At One year follow up there is no recurrence and reasonably good function around the ankle joint is maintained.

Primary Giant Cell Tumours have been traditionally treated with curettage of the lesion followed by bone grafts/bone cement. Recurrent cases often require aggressive management. The adjuvant treatment used in our case offered good stability and allowed early mobilization of the ankle joint. This case substantiates the use of bone cement in the treatment of recurrent Giant Cell Tumour of distal tibia whenever the articular integrity is intact with reasonably good functional outcomes. However, a periodic follow-up is still recommended to watch-out for late re-recurrences.

#### KEYWORDS

GCT, Distal tibia, Curettage, Bone cement, Recurrence.

**HOW TO CITE THIS ARTICLE:** Ambulgekar RK, Thakkar R, Berlia R, et al. Management of a rare recurrence of distal tibial giant cell tumour by sandwich technique. J. Evid. Based Med. Healthc. 2016; 3(16), 650-655.

DOI: 10.18410/jebmh/2016/148

**INTRODUCTION:** First described by Jaffe et al in 1940, giant cell tumour constitutes 20% of all the skeletal neoplasms with a higher rate of recurrence <sup>(1,2,3,4,5)</sup> after excision. Most common sites for the involvement are distal femur<sup>(6)</sup> and proximal tibia followed by the distal end of radius. Ankle and foot involvement is rare <4%. It is more common in females with age group predominance of 20-55 years.<sup>(7,8)</sup> It is described typically as an expansile lesion involving the epiphysio-metaphyseal region of long bones. Typically the patient has pain in the affected site which is dull aching type and there is a history of trauma or pathological fractures that drives the attention of the patient to the condition.<sup>(9,10)</sup> Pathological fractures are seen in 12% of patients at the time of presentation. There can

also be swelling and joint stiffness.

The diagnosis of giant cell tumour of bones depends mainly on clinical and radiological examination <sup>(9)</sup> (plain X-ray and Computerized Tomography scan) of the site of the lesion. The treatment of Giant Cell Tumour is directed towards local control without sacrificing joint function. This can be achieved by intralesional curettage<sup>(1,7,11,12,13)</sup> with autograft<sup>(6)</sup> reconstruction by packing the cavity of the excised tumour with morselised iliac corticocancellous bone or using bone cement as packaging material for the defect. Another modality is use of adjuvants like pulsatile lavage, hydrogen peroxide<sup>(14,15,16)</sup> phenol cauterization, Burr<sup>(2,17,18)</sup> and Liquid nitrogen.

**CASE REPORT:** A 32-year-old female patient daily waged labourer by occupation came to our hospital with the complaints of pain in the left ankle and swelling present in left distal tibia around the ankle joint since 5 months. She related the pain to the history of trauma which occurred to her 18 months ago with twisting injury to the left ankle with gradually increasing swelling around distal tibia. Pain was dull aching and aggravated by prolonged standing and

Submission 22-01-2016, Peer Review 06-02-2016,

Acceptance 15-02-2016, Published 25-02-2016.

Corresponding Author:

Dr. Rajesh Ambulgekar,

Professor & HOD, Orthopaedics,

Dr. Shankarrao Chavan Government Medical College & Hospital,

Vishnupuri-431606, Maharashtra.

E-mail: drambulgekarrr@gmail.com,

drthakkarrohit@gmail.com

DOI: 10.18410/jebmh/2016/148

walking and was relieved by rest. There was no history of any fever, night cries, loss of weight, and loss of appetite present. The family, occupational, recreational and drug histories were not significant. Patients preoperative x-ray findings of previous operation were- Lytic lesion in epiphysio-metaphyseal region with eccentric lesion within the confines of the cortex (figure 1). Patient's previous MRI features were suggestive of Giant Cell Tumours of distal end tibia (figure 2). Patient was treated 18 months ago in some private hospital with intralesional curettage of the swelling followed by the ipsilateral iliac corticocancellous bone grafting<sup>(6)</sup> procedure. Patient's histopathology report confirmed Giant Cell Tumours grade 1 (figure 3). Patient was alright for 9 months when she again experienced the same clinical symptoms like increased in size of the swelling, tenderness and inability to walk due to pain with disturbances of her daily routine activities. Patient came to our hospital with these symptoms. The general physical and systemic examinations were within normal limits. On local examination, the attitude of the limb was neutral. There was diffuse swelling on the anterolateral border of the left distal tibia 8x8x4cms with well-defined margins, smooth surface and bony deep swelling. Skin over the swelling was normal and localized tenderness was there without any signs of inflammation and raised temperature (figure 4). Crackling and crepitus was felt over the swelling. There were normal ankle movements and no neurological deficits in the foot with normal capillary filling and distal arterial pulsations. X-ray showed well-defined expansile lytic lesion at distal end of left tibia suggestive of giant cell tumour of distal end tibia (figure 5). Patients Computerized Tomography SCAN report revealed that lytic lesion of the lower end of tibia with lesion reaching up to sub articular location with thinning and scalloping of cortex seen and destruction of anterolateral cortex with lesion extending to the soft tissues (figure 6). These features were suggestive of the recurrence <sup>(1,2,3,4,5)</sup> of giant cell tumour of tibia. The condition and routine investigations done in preparation for operative procedure were explained to the patient and we proceeded with our treatment plan of "Sandwich"<sup>(17)</sup> technique. Through the anterolateral incision a large cortical window was made and the left distal tibia was approached and the incision was extended to see the joint involvement. There was no joint involvement seen. The tumour was greyish, non-vascularised, friable mass of approximately 8x8x4cms (figure 7). The tumour was curetted<sup>(1,7,11,12,13)</sup> until normal appearing bone was seen and only a thin rim of subchondral bone was left intact. Thorough extended curettage of the cavity was done in all directions using a high-speed burr<sup>(2,18,19)</sup> (figure 8), with care to avoid contamination of the surrounding soft tissues and all the rough surfaces were made smooth and then a lavage was given with normal saline followed by hydrogen peroxide.<sup>(14,15,16)</sup> The material curetted<sup>(1,7,11,12,13)</sup> out was sent for histopathological examination. The defect created was filled with the bone graft<sup>(6)</sup> (contralateral iliac corticocancellous bone graft harvested) of 1 cms. thickness adjacent to the sub articular surface in the outer layer


followed by the layer of foam gel and then the remaining cavity was filled with layer of polymethylmethacrylate Figure4. Preoperative picture of the patient's foot cement<sup>(6,19,20,21,22)</sup> (figure 9), (figure 10), figure (11). The wound was closed over a suction drain. Patients postoperatively x-ray showed tumour excised and graft in place (figure 12). Postoperatively partial-weight-bearing crutch walking was started immediately. The patient was advised physical therapy with ankle movements active and passive and was discharged on post op day 12 after suture removal. Her histopathology report stated giant cell tumour grade 1 (figure 13). Patient was followed up on 1<sup>st</sup>, 2<sup>nd</sup>, 3<sup>rd</sup>, 6 and 9<sup>th</sup> month. Follow up x-rays and pictures of patient (figure 14), (figure 15) and (figure 16).



**Fig. 1: Pre-Operative x-ray of previous operation done in private hospital**



**Fig. 2: Pre-Operative MRI SCAN of previous operative procedure in private hospital**




**Fig. 3: Histopathology report of previous operation done in private hospital**



**Fig. 4: Pre-Operative picture of the patient's foot**




**Fig. 5: Pre-Operative x-ray of the patient after recurrence of tumour**



**Fig. 6: Pre-Operative CT scan of the patient after the recurrence of tumour**



**Fig. 7: Intra operative picture showing large cortical window created**



**Fig. 8: Intra-operative picture showing the use of burr**



**Fig. 9: Intra-operative picture showing the placement of the graft**



**Fig. 10: Intra-operative picture showing the placement of the gel foam layer**




**Fig. 11: Intra-operative picture showing the placement of the cement**





**Fig. 12: Immediate post-Operative x-ray of the patient**



**Fig. 13: Post-Operative histopathology report of the patient**



**Fig. 14: Patients 3<sup>rd</sup> month x-ray showing the graft and cement with maintained articular margins**



**Fig. 15: 3rd month picture of the patient walking comfortably**



**Fig. 16: 3rd month picture of the patient standing comfortably on the operated leg**

**DISCUSSION:** The treatment of Giant Cell Tumour is directed towards local control without sacrificing joint function. This has traditionally been achieved by intralesional curettage<sup>(1,7,11,12,13)</sup> with autograft<sup>(6)</sup> reconstruction by packing the cavity of the excised tumour with morselised iliac cortico-cancellous bone graft. Regardless of how thoroughly performed, curettage leaves

microscopic disease in the bone and hence has a reported recurrence<sup>(1,2,3,4,5)</sup> rate as high as 60%. Bone graft is used as it undergoes remodelling along the stress lines and once it is incorporated the reconstruction is permanent. In our procedure we used the cement<sup>(6,19,20,21,22)</sup> as the cement has methylmethacrylate monomer which is cytotoxic and its thermal effect and hyperthermia produced after its setting helps extend the boundary of the tumour kill. It has also advantage of immediate structural support and rapid weight bearing. There is a problem of late articular degeneration in the sub articular lesions where the amount of residual bone after the curettage is less than 5 mm, a multilayer reconstruction technique is recommended. A layer of bone graft adjacent to the sub articular surface followed by layer of gel foam over this and finally the remaining cavity is packed with cement<sup>(6,19,20,21,22)</sup>. This helps to reduce the heat damage from the curing cement and the sub articular bone graft after consolidation should prevent articular degeneration.

The changing trends in the management of bone tumours are from limb sacrifice to limb salvage and currently preservation of limb functionality. Amputation surgeries have become only of historical significance. With each recurrence these tumours tend to get aggressive. Such aggressive lesions can also be treated with extended tumour resection followed by ankle arthrodesis or endoprosthetic replacement.<sup>(23,24,25,26,27)</sup> Ankle Arthrodesis following tumour excision can be achieved by vascularized autografts, non-vascularized autografts, allografts, or pasteurized autografts. Despite good functional outcomes, limitations for this procedure include stiff ankle, a long period of recovery, infection, and non-union. Similar to mega-prosthesis in the treatment of aggressive Giant Cell Tumours around the knee, ankle endoprosthesis have been introduced. Their side effects are deep infection, implant loosening and high cost. In our patient the distal tibial articular cartilage was intact so we decided to proceed with sandwich<sup>(17)</sup> technique.

**CONCLUSION:** Giant Cell Tumours affecting the distal tibia are rare to encounter. Bony defects can be filled with autografts with bone cement. However, when there is recurrence<sup>(1,2,3,4,5)</sup> there should be extended curettage<sup>(1,7,11,12,13)</sup> done with the use of adjuvants like phenol, hydrogen peroxide,<sup>(14,15,16)</sup> burr<sup>(2,18,19)</sup> and then the bone grafts and bone cement should be used as void fillers by sandwich technique to achieve local control of the disease. This modality of treatment offers chances of less recurrence, good stability and early ankle mobilization is possible.

## BIBLIOGRAPHY

1. Carrasco CH, Murray JA. Giant cell tumours. *Orthop Clin North Am* 1989;20(3):395-405.
2. Prosser GH, Baloch KG, Tillman RM, et al. Does curettage without adjuvant therapy Provide low recurrence rates in giant-cell tumors of bone? *Clin Ortho Relat Res* 2005;435:211-8.
3. Frassica FJ, Gorski JP, Pritchard DJ, et al. A comparative analysis of subchondral replacement with polymethylmethacrylate or autogenous bone grafts in dogs. *Clin Orthop Relat Res* 1993;293:378-90.
4. Arbeitsgemeinschaft Knochentumoren, Becker WT, Dohle J, et al. Local recurrence of giant cell tumour of bone after intralesional treatment with and without adjuvant therapy. *J Bone Joint Surg Am* 2008;90(5):1060-7.
5. Campanacci M, Baldini N, Boriani S, et al. Giant-cell tumour of bone. *J Bone Joint Surg Am* 1987;69(1):106-14.
6. Chen TH, Su YP, Chen WM. Giant cell tumours of the knee: Subchondral bone integrity affects the outcome. *Int Orthop* 2005;29(1):30-4.
7. Sung HW, Kuo DP, Shu WP, et al. Giant cell tumour of bone: Analysis of two hundred and eight cases in Chinese patients. *J Bone Joint Surg Am* 1982;64(5):755-61.
8. Settakorn J, Lekawanvijit S, Arpornchayanon O, et al. Spectrum of bone tumours in Chiang Mai university hospital, Thailand according to WHO classification 2002: A study of 1,001 cases. *J Med Assoc Thai* 2006;89(6):780-7.
9. Canale TS. Chapter 21: Benign/aggressive tumours of bone in *Campbell's operative orthopaedics* Ed. Mosby, New York, NY, USA 2007;1(11<sup>th</sup> edition):883-886.
10. Turcotte RE. Giant cell tumour of bone. *Orthop Clin North Am* 2006;37(1):35-51.
11. Bapat MR, Narlawar RS, Pimple MK, et al. Giant cell tumour of talar body. *J Postgrad Med* 2000;46(2):110-111.
12. Dhillon MS, Singh B, Gill SS, et al. Management of giant cell tumour of the tarsal bones: A report of nine cases and a review of the literature. *Foot Ankle* 1993;14(5):265-272.
13. Persson BM, Ekelund L, Lovdahl R, et al. Favourable results of acrylic cementation for giant cell tumours. *Acta Orthopaedica Scandinavica* 1984;55(2):209-214.
14. Dürre HR, Maier M, Jansson V, et al. Phenol as an adjuvant for local control in the treatment of giant cell tumour of the bone. *European Journal of Surgical Oncology* 1999;25(6):610-618.
15. Wooldridge AN, Kolovich GP, Crist MK, et al. Predictors of local recurrence in high-grade soft tissue sarcomas; Hydrogen peroxide as a local adjuvant. *orthopedics* 2013;36(2):e207-e215. <http://dx.doi.org/10.3928/01477447-20130122-24>.
16. Nicholson NC, Ramp WK, Kneisl JS, et al. Hydrogen peroxide inhibits giant cell tumour and osteoblast metabolism in vitro. *Clin Orthop Relate Res* 1998;347:250-60.
17. Campanacci M, Capanna R, Fabbri N, et al. Curettage of giant cell tumour of bone. Reconstruction with subchondral grafts and cement. *Chir Organi Mov* 1990;75(1):212-3.

18. Blackley HR, Wunder JS, Davis AM, et al. Treatment of giant-cell tumours of long bones with curettage and bone-grafting. *Journal of Bone and Joint Surgery American* 1999;81(6):811–820.
19. Turcotte RE, Wunder JS, Isler MH, et al. Giant cell tumour of long bone: a canadian sarcoma group study. *Clinical Orthopaedics and Related Research* 2002;397:248–258.
20. Bini SA, Gill K, Johnston JO. Giant cell tumour of bone. Curettage and cement reconstruction. *Clinical Orthopaedics and Related Research* 1995;321:245–50.
21. Nelson DA, Barker ME, Hamlin BH. Thermal effects of acrylic cementation at bone tumour sites. *Int J Hyperther* 1997;13(3):287–306.
22. Ward WG, Li G. Customized treatment algorithm for giant cell tumour of bone: Report of a series. *Clin Orthop Relat Res* 2002;397:259–270.
23. Ben Amor H, Zouari M, Karray S, et al. Giant cell tumors of the distal end of the radius treated by resection arthrodesis. *Acta Orthop Belg* 1998;64:41–6.
24. Kumta SM, Leung PC, Yip K, et al. Vascularized bone grafts in the treatment of juxta-articular giant cell tumours of the bone. *J Reconstr Microsurg* 1998;14:185–90.
25. Ihara K, Doi K, Sakai K, et al. Vascularized fibular graft after excision of giant cell tumour of the distal radius a case report. Curettage and cement reconstruction 1999;359:189–196.
26. Tsuchiya H, Tomita K, Shinokawa Y, et al. The Ilizarov method in the management of giant cell tumours of the proximal tibia. *J Bone Joint Surg Br* 1996;78:264–9.
27. Vidyadhara S, Rao SK. Techniques in the management of juxta-articular aggressive and recurrent giant cell tumours around the knee. *Eur J Surg Oncol* 2007;33(2):243–51.